The Tencent-backed owner of pharmaceutical platform Miaoshou Doctor has raised a series F round from new and returning investors, six months after it completed a series E.

Yuanxin Technology, a China-based telemedicine app operator backed by internet company Tencent, secured RMB1.5bn ($232m) yesterday in series F funding.

State-owned financial services firm Bank of China’s BOC International subsidiary took part in the round, which included Ab Initio Capital, B Capital Group, Citic Securities, E Fund Management, Hel Ved Capital Management, Ince Capital, Index Capital, Kunling Capital, Orbimed, Qiming Venture Partners’s Springhill Fund and United Overseas Bank.

Founded in 2015, Yuanxin Technology runs a pharmaceutical platform dubbed Miaoshou Doctor…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn